Navigation Links
Covance to Present at the Morgan Stanley Global Healthcare Conference
Date:9/7/2012

PRINCETON, N.J., Sept. 7, 2012 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today announced that it will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 11, 2012 at 9:10 a.m. (ET).  Investors may access a live webcast of the presentation at www.covance.com.  In order to register and download any necessary software, please log on 10 minutes early.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $2 billion, global operations in more than 30 countries, and more than 11,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release (and in the webcast announced in this press release), which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue, earnings growth, and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories, fluctuations in currency exchange rates, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
2. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
3. Amgen To Present At The Morgan Stanley Global Healthcare Conference
4. Champions Oncology to Present at Rodman & Renshaw Conference
5. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
6. Cumberland Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York
7. PDL BioPharma to Present at Upcoming Investor Conferences
8. CVS Caremark to Present at Morgan Stanley Global Healthcare Conference
9. GP Strategies to Present at the BMO Capital Markets 12th Annual Back to School Education Conference
10. Depomed To Present At Morgan Stanley 2012 Healthcare Conference
11. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... Sapheneia and Scannerside received FDA 510(k) clearance ... a third-party Vendor neutral CT product that makes it ... with current MITA standards. ... is specifically designed to provide CT operators, prior to ... over a predefined threshold. Scannerside Dose Check is intended ...
(Date:9/5/2017)... Sept. 5, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral ... concluded its meeting with the U.S. Food and Drug ... formulation. At the ... pathway for submission of ORMD-0801, would be a Biologics ...
(Date:8/31/2017)... PM360,s annual Innovations Issue, published in ... innovations happening across the industry. Established six years ago, ... providing a comprehensive look at the newest and most ... innovative companies, startups, divisions, products, services, and strategies from ... "Everyone in this industry wants to do better—in all ...
Breaking Medicine Technology:
(Date:9/25/2017)... , ... September 25, 2017 , ... ... of the nationally syndicated The Sharon Kleyne Hour Power of Water, Global Climate ... us to shift our Olympic focus from a once-every-four-years series of events to ...
(Date:9/25/2017)... New York (PRWEB) , ... September 25, 2017 , ... ... due to severe Osteoarthritis and multiple health issues. As a cabaret and theater producer, ... walking as her main source of transportation in New York City, so she had ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... research, today announces that 30 of its domain experts will present on ... at upcoming industry conferences and webinars. Drawing on broad and deep industry ...
(Date:9/25/2017)... New Port Richey, FL (PRWEB) , ... September 25, 2017 , ... ... new New Port Richey, Fla. location at 5304 Main Street as an interventional pain ... pain of the spine and extremities. He joins PPOA from private practice In Brooksville, ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... is excited to announce the next generation for LASIK in Manhattan with Contoura ... the most technologically advanced laser systems available in the United States to correct ...
Breaking Medicine News(10 mins):